Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells

  • Authors:
    • Jan Hrabeta
    • Tomas Groh
    • Mohamed Ashraf Khalil
    • Jitka Poljakova
    • Vojtech Adam
    • Rene Kizek
    • Jiri Uhlik
    • Helena Doktorova
    • Tereza Cerna
    • Eva Frei
    • Marie Stiborova
    • Tomas Eckschlager
  • View Affiliations

  • Published online on: June 29, 2015     https://doi.org/10.3892/ijo.2015.3066
  • Pages: 971-980
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Neuroblastoma is the most common cancer in infants and the fourth most common cancer in children. Aggressive cell growth and chemoresistance are notorious obstacles in neuroblastoma therapy. Exposure to the anticancer drug ellipticine inhibits efficiently growth of neuroblastoma cells and induces apoptosis in these cells. However, ellipticine induced resistance in these cells. The upregulation of a vacuolar (V)-ATPase gene is one of the factors associated with resistance development. In accordance with this finding, we found that levels of V-ATPase protein expression are higher in the ellipticine-resistant UKF-NB-4ELLI line than in the parental ellipticine-sensitive UKF-NB-4 cell line. Treatment of ellipticine-sensitive UKF-NB-4 and ellipticine-resistant UKF-NB-4ELLI cells with ellipticine-induced cytoplasmic vacuolization and ellipticine is concentrated in these vacuoles. Confocal microscopy and staining of the cells with a lysosomal marker suggested these vacuoles as lysosomes. Transmission electron microscopy and no effect of an autophagy inhibitor wortmannin ruled out autophagy. Pretreatment with a V-ATPase inhibitor bafilomycin A and/or the lysosomotropic drug chloroquine prior to ellipticine enhanced the ellipticine‑mediated apoptosis and decreased ellipticine-resistance in UKF-NB-4ELLI cells. Moreover, pretreatment with these inhibitors increased formation of ellipticine-derived DNA adducts, one of the most important DNA-damaging mechanisms responsible for ellipticine cytotoxicity. In conclusion, resistance to ellipticine in the tested neuroblastoma cells is associated with V-ATPase-mediated vacuolar trapping of this drug, which may be decreased by bafilomycin A and/or chloroquine.
View Figures
View References

Related Articles

Journal Cover

September 2015
Volume 47 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hrabeta, J., Groh, T., Khalil, M.A., Poljakova, J., Adam, V., Kizek, R. ... Eckschlager, T. (2015). Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells. International Journal of Oncology, 47, 971-980. https://doi.org/10.3892/ijo.2015.3066
MLA
Hrabeta, J., Groh, T., Khalil, M. A., Poljakova, J., Adam, V., Kizek, R., Uhlik, J., Doktorova, H., Cerna, T., Frei, E., Stiborova, M., Eckschlager, T."Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells". International Journal of Oncology 47.3 (2015): 971-980.
Chicago
Hrabeta, J., Groh, T., Khalil, M. A., Poljakova, J., Adam, V., Kizek, R., Uhlik, J., Doktorova, H., Cerna, T., Frei, E., Stiborova, M., Eckschlager, T."Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells". International Journal of Oncology 47, no. 3 (2015): 971-980. https://doi.org/10.3892/ijo.2015.3066